Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation, and its news flow reflects active clinical development, collaborations and capital markets activity. Company updates frequently highlight progress with cemsidomide, an investigational IKZF1/3 degrader in development for relapsed/refractory multiple myeloma and certain lymphomas, as well as broader pipeline and platform achievements.
News for C4 Therapeutics often centers on clinical data milestones, such as Phase 1 results for cemsidomide in combination with dexamethasone, acceptance of data for oral presentation at scientific meetings, and plans for registrational trials like the Phase 2 MOMENTUM study. Releases also cover developments in non-Hodgkins lymphoma cohorts and updates on other degrader programs, including CFT8919 for EGFR-mutant non-small cell lung cancer and CFT1946 for BRAF V600 mutant solid tumors.
Investors following CCCC news will also see collaboration announcements and research milestones. Examples include the clinical trial collaboration and supply agreement with Pfizer to evaluate cemsidomide with elranatamab in multiple myeloma, milestone achievements in partnerships with Biogen, Roche and Merck KGaA, Darmstadt, Germany, and regulatory steps such as IND acceptance for BIIB142, an IRAK4 degrader designed by C4 Therapeutics.
Financial and corporate updates are another key news category. The company regularly reports quarterly financial results, cash runway guidance, equity offerings and changes to its capital structure via press releases and Form 8-K filings. For readers tracking CCCC, this news page aggregates these clinical, scientific, collaboration and financing updates in one place, making it easier to monitor how C4 Therapeutics is advancing its targeted protein degradation pipeline over time.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, will participate in the UBS Targeted Protein Degradation Day, held virtually on July 15, 2024. The company's management will engage in a fireside chat from 12:00 pm ET to 12:30 pm ET. A live webcast of the event will be accessible on the Investors section of C4 Therapeutics' website, with a replay available for 30 days post-event.
C4 Therapeutics has appointed Ron Cooper as the new Chairman of the Board.
He brings extensive global pharmaceutical and biotechnology experience.
Bruce Downey will remain on the Board and chair the Organization, Leadership, and Compensation Committee.
Glenn Dubin is stepping down from the Board.
C4 Therapeutics aims to become a fully integrated biotechnology company, focusing on targeted protein degradation science.
Ron Cooper's past roles include leadership positions at Albireo Pharma and Bristol-Myers Squibb.
His experience spans across discovery, development, and commercialization of pharmaceutical products.
CEO Andrew Hirsch expressed excitement about Cooper's appointment and the future growth of C4 Therapeutics.
C4 Therapeutics, a biopharmaceutical company, reported strong financial results for the first quarter of 2024. They earned an $8 million payment from Biogen, established a research collaboration with Merck KGaA, and advanced Phase 1 trials for CFT7455 and CFT1946. The company's cash position stood at $299.2 million, providing runway into 2027.
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.